参麦注射液联合化疗治疗中晚期非小细胞肺癌临床观察  

The Clinical Observation of Advanced Non small Cell Lung Cancer Treated with ShenMai Injection Combined with the Chemotherapy

作　　者：郭志峰[1] 韩建国[1] 杨艳[1] 孔凡龙[1] 王小林[1] 

机构地区：[1]赤峰市医院肿瘤内二科,内蒙古赤峰024000

出　　处：《内蒙古医学杂志》2010年第10期1179-1181,共3页Inner Mongolia Medical Journal

摘　　要：目的:评价参麦注射液联合紫杉醇(PTX)加顺铂(PDD)组成的TP方案全身化疗治疗中晚期非小细胞肺癌(NSCLC)的疗效和毒副反应。方法:将62例晚期NSCLC患者随机分为治疗组31例和对照组31例,分别接受TP方案加参麦注射液或单纯TP方案化疗。结果:治疗组有效率51.61%高于对照组有效率48.39%,差异无统计学意义(P>0.05);治疗组毒性反应低于对照组(P<0.05)。治疗组生活质量明显改善(P<0.05)。结论:参麦注射液配合TP方案化疗在治疗非小细胞肺癌中可提高化疗疗效,减轻化疗毒性,提高患者生活质量。Objective：To evaluate the efficacy of combination ShenMai injection with PTX and DDP chemotherapy（TP regimen）for the treatment of advanced non-small cell lung cancer（NSCLC）.Methods：62 patients were devided into control group（ShenMai injection combined with chemotherapy,31 cases）and treatment group（chemotherapy alone,31 cases） randomly.Results：The overall response rate of treatment group and control group were 51.61% and 48.39% respectively,there was no significant difference between the two group（P〈0.05）;The life quality and relieved chemotherapy toxity of patients in treatment group were superior to the patients in control group（P〈0.05）.Conclusion：ShenMai injections can improve the curative effect of advanced non-small cell lung cancer,decrease toxic reaction and improve quality of life for advanced NSCLC.

关 键 词：参麦注射液 非小细胞肺癌 紫杉醇 顺铂 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]